Study of the Transmission of Anti-interferon Type 1 Alpha Autoantibodies From Mother to Child Via the Placental Barrier
NCT ID: NCT06371235
Last Updated: 2024-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
250 participants
INTERVENTIONAL
2024-09-30
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
NCT00456118
Role of Anti-C1q Autoantibodies in Pregnancy
NCT06317467
An Observational Study on Teriflunomide-exposed Pregnancies
NCT03198351
Neutrophil Extracellular Traps Mediate Antiphospholipid Antibody-induced Pregnancy Loss
NCT03735108
The Role of Pro-angiogenic Immune Cells in Human Pregnancies
NCT01177020
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pregnant women
Pregnant woman over 18 years old
\- Woman whose gestational age is less than 30 weeks
Pregiferon
This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pregiferon
This Study aims to study the transmission of anti-interferon alpha autoantibodies from mother to child viaplacental barrier
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Woman whose gestational age is less than 30 weeks.
* Having agreed to carry out an assay of anti-IFN alpha IgG auto-Ac before 30 weeks
* Give birth in the inclusion center
* Suffering from a pathology frequently associated with the presence of these anti-autoantibodies IFN alpha (lupus, severe COVID-19, myasthenia gravis, incontinentia pigmenti, hypoparathyroidism, adrenal insufficiency, diffuse candidiasis, Biermer's disease, dysthyroidism, type 1 diabetes, celiac disease, auto-thyroid disease immune system such as Graves' disease, Hashimoto's thyroiditis) or knowing its positive anti-IFN alpha autoantibody status
* Affiliated with the Social Security system
Exclusion Criteria
* Patient who received an organ transplant
* Patient undergoing immunotherapy, stem cell therapy and/or other malignancy maternal, under heavy treatment (chemotherapy) less than 6 months before inclusion
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CerbaXpert
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A00739-38
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.